Immune checkpoint inhibitors(ICIs),as a first-line drug for clinical treatment of tumors,can cause a series of immune-related adverse events(irAEs)during the treatment,involving multiple organs and systems.The most serious of them are ICIs-related cardiovascular adverse events,including myocarditis,pericarditis,atherosclerotic cardiovascular disease,arrhythmia,vasculitis,and venous thromboembolism.Although the incidence of ICIs-related cardiovascular adverse events is low,the mortality rate is high,which has seriously affected the quality of life and long-term prognosis of cancer patients.Therefore,early identification and timely intervention are very important.This article mainly reviews the epidemiology,pathogenesis,diagnosis and treatment of ICIs-related cardiovascular adverse events,in order to provide reference for clinical work.
维普
万方数据